Source: BIOCENTURY

Dezima Pharma: Amgen buys Dezima

Amgen Inc. (NASDAQ:AMGN) will acquire Dezima Pharma B.V. (Naarden, the Netherlands) for $300 million up front and up to $1.25 billion in milestones, plus potential royalties. The driver of the deal is TA-8995, a cholesteryl ester transfer protein (CETP) inhibitor that has completed Phase IIb testing to treat dyslipidemia.Amgen said that along with its PCSK9 inhibitor Repatha evolocumab, it will be able to offer multiple mechanisms for lowering cholesterol.Forbion Capital Partners and BioGeneration Ventures seeded Dezima in 2012 and led the company's $13 million series A round in 2013.Dezima has exclusive, worldwide rights, excluding certain Asian territories, to TA-8995 from Mitsubishi Tanabe Pharma Corp. (Tokyo:4508). The Japanese company will receive a portion of the upfront acquisition payment and the milestones.The parties expect the deal to close in 4Q15.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Estimated Annual Revenue

Estimated Employees

Rob de Ree's photo - CEO of Dezima Pharma

CEO

Rob de Ree

CEO Approval Rating

69/100

Dezima Pharma is engaged in the development of novel drugs to treat cardiovascular disease related to dyslipidemia.

Dezim...
Read more